Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.

Ted White Biography and Net Worth

CEO of Verrica Pharmaceuticals

Mr. White has served as Verrica Pharmaceuticals’ President and Chief Executive Officer since December 2017 and as a member of our Board of Directors since May 2018. Previously, he was President and General Manager at Almirall, a global pharmaceutical company, and the parent company of Aqua Pharmaceuticals, based in Barcelona, Spain, with a focus on Medical Dermatology. Prior to his time at Aqua Pharmaceuticals, Mr. White was at Novartis, where he served in a number of roles, including as Managing Director. He holds an MBA from St. Joseph’s University and a BA in General Arts from Villanova University.

What is Ted White's net worth?: The estimated net worth of Ted White is at least $173,634.00 as of July 22nd, 2024. Mr. White owns 250,121 shares of Verrica Pharmaceuticals stock worth more than $173,634 as of December 21st. This net worth estimate does not reflect any other assets that Mr. White may own. Additionally, Mr. White receives an annual salary of $914,680.00 as CEO at Verrica Pharmaceuticals. Learn More about Ted White's net worth.
How old is Ted White?: Mr. White is currently 59 years old. There are 3 older executives and no younger executives at Verrica Pharmaceuticals. Learn More on Ted White's age.
What is Ted White's salary?: As the CEO of Verrica Pharmaceuticals Inc., Mr. White earns $914,680.00 per year. Learn More on Ted White's salary.
How do I contact Ted White?: The corporate mailing address for Mr. White and other Verrica Pharmaceuticals executives is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. Verrica Pharmaceuticals can also be reached via phone at (434) 453-3300 and via email at [email protected]. Learn More on Ted White's contact information.
Has Ted White been buying or selling shares of Verrica Pharmaceuticals?: Ted White has not been actively trading shares of Verrica Pharmaceuticals during the last quarter. Most recently, Ted White sold 32,469 shares of the business's stock in a transaction on Monday, July 22nd. The shares were sold at an average price of $7.06, for a transaction totalling $229,231.14. Following the completion of the sale, the chief executive officer now directly owns 250,121 shares of the company's stock, valued at $1,765,854.26. Learn More on Ted White's trading history.
Who are Verrica Pharmaceuticals' active insiders?: Verrica Pharmaceuticals' insider roster includes Matt Davidson (Major Shareholder), A. Davis (CFO), Christopher Hayes (Insider), Paul Manning (Director), and Ted White (CEO). Learn More on Verrica Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Verrica Pharmaceuticals?: During the last year, Verrica Pharmaceuticals insiders bought shares 3 times. They purchased a total of 380,768 shares worth more than $2,481,592.76. During the last year, insiders at the sold shares 2 times. They sold a total of 57,930 shares worth more than $408,985.80. The most recent insider tranaction occured on July, 22nd when CEO Ted White sold 32,469 shares worth more than $229,231.14. Insiders at Verrica Pharmaceuticals own 42.6% of the company. Learn More about insider trades at Verrica Pharmaceuticals.
Information on this page was last updated on 7/22/2024.

Ted White Insider Trading History at Verrica Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/22/2024	Sell	32,469	$7.06	$229,231.14	250,121
7/24/2023	Sell	50,677	$4.83	$244,769.91	128,789
7/5/2022	Buy	23,809	$2.10	$49,998.90	29,466
6/4/2021	Buy	4,000	$9.95	$39,800.00	21,966
8/13/2020	Buy	10,661	$6.28	$66,951.08	17,966
8/20/2018	Buy	300	$16.36	$4,908.00
8/15/2018	Buy	2,505	$15.69	$39,303.45

Ted White Buying and Selling Activity at Verrica Pharmaceuticals

Verrica Pharmaceuticals Company Overview

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Today's Range

Now: $0.69

$0.65

$0.74

50 Day Range

MA: $1.11

$0.64

$1.68

2 Week Range

Now: $0.69

$0.61

$11.41

Volume

1,536,957 shs

Average Volume

498,475 shs

Market Capitalization

$31.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4

AI breakthrough about to upend industry

From Porter & Company | Ad

I urge you to watch it now.

Ted White Biography and Net Worth

What is Ted White's net worth?

How old is Ted White?

What is Ted White's salary?

How do I contact Ted White?

Has Ted White been buying or selling shares of Verrica Pharmaceuticals?

Who are Verrica Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Verrica Pharmaceuticals?